{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:57:03Z","timestamp":1794715023506,"version":"4.9.1"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Approximately 40% of treatments of chronic and recurrent osteomyelitis fail in part due to bacterial persistence.\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    , the predominant pathogen in human osteomyelitis, is known to persist by phenotypic adaptation as small-colony variants (SCVs) and by formation of intracellular reservoirs, including those in major bone cell types, reducing susceptibility to antibiotics. Intracellular infections with\n                    <jats:italic>S. aureus<\/jats:italic>\n                    are difficult to treat; however, there are no evidence-based clinical guidelines addressing these infections in osteomyelitis. We conducted a systematic review of the literature to determine the demonstrated efficacy of all antibiotics against intracellular\n                    <jats:italic>S. aureus<\/jats:italic>\n                    relevant to osteomyelitis, including protein biosynthesis inhibitors (lincosamides, streptogramins, macrolides, oxazolidines, tetracyclines, fusidic acid, and aminoglycosides), enzyme inhibitors (fluoroquinolones and ansamycines), and cell wall inhibitors (beta-lactam inhibitors, glycopeptides, fosfomycin, and lipopeptides). The PubMed and Embase databases were screened for articles related to intracellular\n                    <jats:italic>S. aureus<\/jats:italic>\n                    infections that compared the effectiveness of multiple antibiotics or a single antibiotic together with another treatment, which resulted in 34 full-text articles fitting the inclusion criteria. The combined findings of these studies were largely inconclusive, most likely due to the plethora of methodologies utilized. Therefore, the reported findings in the context of the models employed and possible solutions for improved understanding are explored here. While rifampicin, oritavancin, linezolid, moxifloxacin and oxacillin were identified as the most effective potential intracellular treatments, the scientific evidence for these is still relatively weak. We advocate for more standardized research on determining the intracellular effectiveness of antibiotics in\n                    <jats:italic>S. aureus<\/jats:italic>\n                    osteomyelitis to improve treatments and patient outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41413-022-00227-8","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T04:03:31Z","timestamp":1660277011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis"],"prefix":"10.1038","volume":"10","author":[{"given":"Anja R.","family":"Zelmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjy","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"227_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ajpath.2020.02.007","volume":"190","author":"MI Hofstee","year":"2020","unstructured":"Hofstee, M. I. et al. Current concepts of osteomyelitis: from pathologic mechanisms to advanced research methods. Am J Pathol 190, 1151\u20131163 (2020).","journal-title":"Am J Pathol"},{"key":"227_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","volume":"364","author":"DP Lew","year":"2004","unstructured":"Lew, D. P. & Waldvogel, F. A. Osteomyelitis. Lancet 364, 369\u2013379 (2004).","journal-title":"Lancet"},{"key":"227_CR3","unstructured":"Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2020 Annual Report. 1\u2013474 (AOA, Adelaide, 2020)."},{"key":"227_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2106\/JBJS.M.00285","volume":"96","author":"SM Kurtz","year":"2014","unstructured":"Kurtz, S. M., Ong, K. L., Lau, E. & Bozic, K. J. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. J. Bone Jt. Surg. 96, 624\u2013630 (2014).","journal-title":"J. Bone Jt. Surg."},{"key":"227_CR5","first-page":"1","volume":"7","author":"EA Masters","year":"2019","unstructured":"Masters, E. A. et al. Evolving concepts in bone infection: redefining \u201cbiofilm\u201d, \u201cacute vs. chronic osteomyelitis\u201d. \u201c Immune Proteome\u201d \u201cLocal Antibiot. Ther.\u201d. Bone Res. 7, 1\u201318 (2019).","journal-title":"\u201c Immune Proteome\u201d \u201cLocal Antibiot. Ther.\u201d. Bone Res."},{"key":"227_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5435\/00124635-200305000-00008","volume":"11","author":"CG Zalavras","year":"2003","unstructured":"Zalavras, C. G. & Patzakis, M. J. Open fractures: evaluation and management. J. Am. Acad. Orthop. Surg. 11, 212\u2013219 (2003).","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"227_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.injury.2016.09.019","volume":"49","author":"WJ Metsemakers","year":"2018","unstructured":"Metsemakers, W. J. et al. Infection after fracture fixation: current surgical and microbiological concepts. Injury 49, 511\u2013522 (2018).","journal-title":"Injury"},{"key":"227_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/jor.24293","volume":"37","author":"EM Schwarz","year":"2019","unstructured":"Schwarz, E. M. et al. 2018 international consensus meeting on musculoskeletal infection: research priorities from the general assembly questions. J. Orthop. Res. 37, 997\u20131006 (2019).","journal-title":"J. Orthop. Res."},{"key":"227_CR9","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/j.diabres.2013.06.010","volume":"101","author":"S Acharya","year":"2013","unstructured":"Acharya, S., Soliman, M., Egun, A. & Rajbhandari, S. M. Conservative management of diabetic foot osteomyelitis. Diabetes Res. Clin. Pract. 101, e18\u2013e20 (2013).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"227_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1302\/2046-3758.108.BJR-2021-0058.R1","volume":"10","author":"IK Sigmund","year":"2021","unstructured":"Sigmund, I. K. et al. Diagnostic accuracy of neutrophil counts in histopathological tissue analysis in periprosthetic joint infection using the ICM, IDSA, and EBJIS criteria. Bone Jt. Res. 10, 536\u2013547 (2021).","journal-title":"Bone Jt. Res."},{"key":"227_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fcimb.2015.00085","volume":"5","author":"J Josse","year":"2015","unstructured":"Josse, J., Velard, F. & Gangloff, S. C. Staphylococcus aureus vs. osteoblast: relationship and consequences in osteomyelitis. Front. Cell. Infect. Microbiol. 5, 85 (2015).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"227_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.22203\/eCM.v042a19","volume":"41","author":"RT Ormsby","year":"2021","unstructured":"Ormsby, R. T. et al. Evidence for osteocyte-mediated bone-matrix degradation associated with periprosthetic joint infection PJI. Eur. Cells Mater. 41, 264\u2013280 (2021).","journal-title":"Eur. Cells Mater"},{"key":"227_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijmm.2009.10.003","volume":"300","author":"JA Wright","year":"2010","unstructured":"Wright, J. A. & Nair, S. P. Interaction of staphylococci with bone. Int. J. Med. Microbiol. 300, 193\u2013204 (2010).","journal-title":"Int. J. Med. Microbiol."},{"key":"227_CR14","doi-asserted-by":"publisher","first-page":"e01910","DOI":"10.1128\/mBio.01910-14","volume":"5","author":"AJ Tande","year":"2014","unstructured":"Tande, A. J. et al. Clinical characteristics and outcomes of prosthetic joint infection caused by small colony variant staphylococci. mBio 5, e01910\u201314 (2014).","journal-title":"mBio"},{"key":"227_CR15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/039139880502801106","volume":"28","author":"CR Arciola","year":"2005","unstructured":"Arciola, C. R., An, Y., Campoccia, D., Donati, M. & Montanaro, L. Etiology of implant orthopedic infections: a survey on 1027 clinical isolates. Int. J. Artif. Organs 28, 1091\u20131100 (2005).","journal-title":"Int. J. Artif. Organs"},{"key":"227_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrmicro1384","volume":"4","author":"RA Proctor","year":"2006","unstructured":"Proctor, R. A. et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4, 295\u2013305 (2006).","journal-title":"Nat. Rev. Microbiol."},{"key":"227_CR17","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1128\/AAC.01145-08","volume":"53","author":"HA Nguyen","year":"2009","unstructured":"Nguyen, H. A. et al. Intracellular activity of antibiotics in a model of human THP-1 Macrophages Infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: Pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrobial Agents Chemother. 53, 1434\u20131442 (2009).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/jac\/dkt072","volume":"68","author":"LG Garcia","year":"2013","unstructured":"Garcia, L. G. et al. Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. J. Antimicrobial Chemother. 68, 1455\u20131464 (2013).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fmicb.2020.00321","volume":"11","author":"J Lee","year":"2020","unstructured":"Lee, J., Zilm, P. S. & Kidd, S. P. Novel research models for Staphylococcus aureus small colony variants (SCV) development: Co-pathogenesis and growth rate. Front. Microbiol. 11, 321 (2020).","journal-title":"Front. Microbiol"},{"key":"227_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1128\/CMR.00069-15","volume":"29","author":"BC Kahl","year":"2016","unstructured":"Kahl, B. C., Becker, K. & L\u00f6ffler, B. Clinical significance and pathogenesis of staphylococcal small colony variants in persistent infections. Clin. Microbiol. Rev. 29, 401\u2013427 (2016).","journal-title":"Clin. Microbiol. Rev."},{"key":"227_CR21","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.injury.2006.04.006","volume":"37","author":"C von Eiff","year":"2006","unstructured":"von Eiff, C., Peters, G. & Becker, K. The small colony variant (SCV) concept\u2014the role of staphylococcal SCVs in persistent infections. Injury 37, S26\u2013S33 (2006).","journal-title":"Injury"},{"key":"227_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ijmm.2017.11.009","volume":"308","author":"J Horn","year":"2018","unstructured":"Horn, J., Stelzner, K., Rudel, T. & Fraunholz, M. Inside job: Staphylococcus aureus host-pathogen interactions. Int. J. Med. Microbiol. 308, 607\u2013624 (2018).","journal-title":"Int. J. Med. Microbiol."},{"key":"227_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1086\/507633","volume":"43","author":"P Sendi","year":"2006","unstructured":"Sendi, P. et al. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 43, 961\u2013967 (2006).","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"227_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1086\/656047","volume":"202","author":"L Tuchscherr","year":"2010","unstructured":"Tuchscherr, L. et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. J. Infect. Dis. 202, 1031\u20131040 (2010).","journal-title":"J. Infect. Dis."},{"key":"227_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00415-18","volume":"9","author":"D Yang","year":"2018","unstructured":"Yang, D. et al. Novel insights into Staphylococcus aureus deep bone infections: The involvement of osteocytes. MBio 9, 1\u201310 (2018). mBio 9:e00415-18.","journal-title":"MBio"},{"key":"227_CR26","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1128\/IAI.67.5.2677-2681.1999","volume":"67","author":"M Jevon","year":"1999","unstructured":"Jevon, M. et al. Mechanisms of internalization of Staphylococcus aureus by cultured human osteoblasts. Infect. Immun. 67, 2677\u20132681 (1999).","journal-title":"Infect. Immun."},{"key":"227_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tim.2008.11.005","volume":"17","author":"C Garzoni","year":"2009","unstructured":"Garzoni, C. & Kelley, W. L. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol. 17, 59\u201365 (2009).","journal-title":"Trends Microbiol."},{"key":"227_CR28","doi-asserted-by":"publisher","first-page":"e02447","DOI":"10.1128\/mBio.02447-19","volume":"10","author":"JL Krauss","year":"2019","unstructured":"Krauss, J. L. et al. Staphylococcus aureus infects osteoclasts and replicates intracellularly. mBio 10, e02447\u201319 (2019).","journal-title":"mBio"},{"key":"227_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmi.2016.06.020","volume":"22","author":"M Strobel","year":"2016","unstructured":"Strobel, M. et al. Post-invasion events after infection with Staphylococcus aureus are strongly dependent on both the host cell type and the infecting S. aureus strain. Clin. Microbiol. Infect. 22, 799\u2013809 (2016).","journal-title":"Clin. Microbiol. Infect."},{"key":"227_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s002530100703","volume":"56","author":"E Alexander","year":"2001","unstructured":"Alexander, E. & Hudson, M. Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl. Microbiol. Biotechnol. 56, 361\u2013366 (2001).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"227_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1302\/2046-3758.92.BJR-2019-0201.R1","volume":"9","author":"T Gao","year":"2020","unstructured":"Gao, T., Lin, J., Zhang, C., Zhu, H. & Zheng, X. Is intracellular Staphylococcus aureus associated with recurrent infection in a rat model of open fracture? Bone Jt. Res. 9, 71\u201376 (2020).","journal-title":"Bone Jt. Res."},{"key":"227_CR32","first-page":"192","volume":"33","author":"A Ballard","year":"2018","unstructured":"Ballard, A. et al. Osteoclasts serve as an intracellular niche for replicating Staphylococcus Aureus. J. Bone Miner. Res. 33, 192 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"227_CR33","doi-asserted-by":"publisher","unstructured":"Krauss, J., Goering, E. & Novack, D. Osteoclasts as an intracellular growth niche for staphylococcus aureus. J. Bone Miner. Res. 31, https:\/\/doi.org\/10.1002\/jbmr.3107 (2017).","DOI":"10.1002\/jbmr.3107"},{"key":"227_CR34","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2106\/00004623-200506000-00022","volume":"87","author":"MJ Bosse","year":"2005","unstructured":"Bosse, M. J., Gruber, H. E. & Ramp, W. K. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. J. Bone Jt. Surg. 87, 1343\u20131347 (2005).","journal-title":"J. Bone Jt. Surg."},{"key":"227_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.22203\/eCM.v025a24","volume":"25","author":"T Hamza","year":"2012","unstructured":"Hamza, T. et al. Intra-cellular Staphylococcus aureus alone causes infection in vivo. Eur. Cells Mater. 25, 341\u2013350 (2012).","journal-title":"Eur. Cells Mater."},{"key":"227_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/bs.aambs.2020.05.001","volume":"112","author":"KE Watkins","year":"2020","unstructured":"Watkins, K. E. & Unnikrishnan, M. Evasion of host defenses by intracellular Staphylococcus aureus. Advances in Applied Microbiology 112, 105\u2013141 (2020).","journal-title":"Advances in Applied Microbiology"},{"key":"227_CR37","doi-asserted-by":"publisher","first-page":"104431","DOI":"10.1016\/j.micpath.2020.104431","volume":"148","author":"A Nasser","year":"2020","unstructured":"Nasser, A., Azimi, T., Ostadmohammadi, S. & Ostadmohammadi, S. A comprehensive review of bacterial osteomyelitis with emphasis on Staphylococcusaureus. Microbial Pathogenesis 148, 104431 (2020).","journal-title":"Microbial Pathogenesis"},{"key":"227_CR38","doi-asserted-by":"publisher","first-page":"115568","DOI":"10.1016\/j.bone.2020.115568","volume":"141","author":"KD Alder","year":"2020","unstructured":"Alder, K. D. et al. Intracellular Staphylococcus aureus in bone and joint infections:a mechanism of disease recurrence, inflammation, and bone and cartilage destruction. Bone 141, 115568 (2020).","journal-title":"Bone"},{"key":"227_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ijantimicag.2014.02.009","volume":"43","author":"N Abed","year":"2014","unstructured":"Abed, N. & Couvreur, P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int. J. Antimicrobial Agents 43, 485\u2013496 (2014).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer, C. B., Bulitta, J. B., Kinzig, M., Holzgrabe, U. & S\u00f6rgel, F. Penetration of antibacterials into bone. Clin. Pharmacokinetics 48, 89\u2013124 (2009).","journal-title":"Clin. Pharmacokinetics"},{"key":"227_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","volume":"81","author":"AK Thabit","year":"2019","unstructured":"Thabit, A. K. et al. Antibiotic penetration into bone and joints: an updated review. Int. J. Infect. Dis. 81, 128\u2013136 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"227_CR42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","volume":"17","author":"S Carryn","year":"2003","unstructured":"Carryn, S. et al. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. 17, 615\u2013634 (2003).","journal-title":"Infect. Dis. Clin."},{"key":"227_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cmi.2021.04.030","volume":"28","author":"L Abad","year":"2022","unstructured":"Abad, L. et al. Lysosomal alkalization to potentiate eradication of intraosteoblastic Staphylococcus aureus in the bone and joint infection setting. Clin. Microbiol. Infect. 28, 135\u2013e1 (2022).","journal-title":"Clin. Microbiol. Infect"},{"key":"227_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/antibiotics8020054","volume":"8","author":"S Bongers","year":"2019","unstructured":"Bongers, S., Hellebrekers, P., Leenen, L. P., Koenderman, L. & Hietbrink, F. Intracellular penetration and effects of antibiotics on Staphylococcus aureus inside human neutrophils: a comprehensive review. Antibiotics 8, 54 (2019).","journal-title":"Antibiotics"},{"key":"227_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00084-17","volume":"31","author":"N Kavanagh","year":"2018","unstructured":"Kavanagh, N. et al. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin. Microbiol. Rev. 31, 1\u201325 (2018).","journal-title":"Clin. Microbiol. Rev."},{"key":"227_CR46","doi-asserted-by":"publisher","first-page":"115225","DOI":"10.1016\/j.diagmicrobio.2020.115225","volume":"99","author":"A Bonnaire","year":"2021","unstructured":"Bonnaire, A. et al. Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp. Diagnostic Microbiol. Infect. Dis. 99, 115225 (2021).","journal-title":"Diagnostic Microbiol. Infect. Dis."},{"key":"227_CR47","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1086\/324626","volume":"34","author":"R Leclercq","year":"2002","unstructured":"Leclercq, R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34, 482\u2013492 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00253-003-1545-7","volume":"64","author":"J Sp\u00ed\u017eek","year":"2004","unstructured":"Sp\u00ed\u017eek, J. & \u0158ezanka, T. Lincomycin, clindamycin and their applications. Appl. Microbiol. Biotechnol. 64, 455\u2013464 (2004).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"227_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrmicro3155","volume":"12","author":"DN Wilson","year":"2014","unstructured":"Wilson, D. N. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat. Rev. Microbiol. 12, 35\u201348 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"227_CR50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s15010-015-0773-y","volume":"43","author":"E Curis","year":"2015","unstructured":"Curis, E. et al. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. Infection 43, 473\u2013481 (2015).","journal-title":"Infection"},{"key":"227_CR51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1128\/AAC.8.2.220","volume":"8","author":"P Nicholas","year":"1975","unstructured":"Nicholas, P., Meyers, B. R., Levy, R. N. & Hirschman, S. Z. Concentration of clindamycin in human bone. Antimicrobial Agents Chemother. 8, 220\u2013221 (1975).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR52","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1365-2125.2012.04292.x","volume":"74","author":"N Bouazza","year":"2012","unstructured":"Bouazza, N. et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br. J. Clin. Pharmacol. 74, 971\u2013977 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"227_CR53","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1128\/AAC.04359-14","volume":"59","author":"F Valour","year":"2015","unstructured":"Valour, F. et al. Antimicrobial activity against intraosteoblastic Staphylococcus aureus. Antimicrobial Agents Chemother. 59, 2029\u20132036 (2015).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jor.20003","volume":"24","author":"JK Ellington","year":"2006","unstructured":"Ellington, J. K. et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J. Orthop. Res. 24, 87\u201393 (2006).","journal-title":"J. Orthop. Res."},{"key":"227_CR55","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/jac\/dkv371","volume":"71","author":"L Tuchscherr","year":"2015","unstructured":"Tuchscherr, L. et al. Staphylococcus aureus develops increased resistance to antibiotics by forming dynamic small colony variants during chronic osteomyelitis. J. Antimicrobial Chemother. 71, 438\u2013448 (2015).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR56","first-page":"143","volume":"10","author":"C Burgaleta","year":"1992","unstructured":"Burgaleta, C., Velasco, G. L., Peletier, R., Messeguer, M. & Pernas, M. The effect of clindamycin on intraphagocytic Staphylococcus aureus in leukocytes from patients with chronic osteomyelitis. Enferm. Infecc. Microbiol Clin. 10, 143\u2013147 (1992).","journal-title":"Enferm. Infecc. Microbiol Clin."},{"key":"227_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.msec.2014.01.008","volume":"37","author":"V Uskokovi\u0107","year":"2014","unstructured":"Uskokovi\u0107, V. & Desai, T. A. Simultaneous bactericidal and osteogenic effect of nanoparticulate calcium phosphate powders loaded with clindamycin on osteoblasts infected with Staphylococcus aureus. Mater. Sci. Eng.: C. 37, 210\u2013222 (2014).","journal-title":"Mater. Sci. Eng.: C."},{"key":"227_CR58","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1128\/AAC.01650-12","volume":"57","author":"J Noore","year":"2013","unstructured":"Noore, J., Noore, A. & Li, B. Cationic antimicrobial peptide LL-37 is effective against both extra-and intracellular Staphylococcus aureus. Antimicrobial Agents Chemother. 57, 1283\u20131290 (2013).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-2-4","volume":"2","author":"JM Harms","year":"2004","unstructured":"Harms, J. M., Schl\u00fcnzen, F., Fucini, P., Bartels, H. & Yonath, A. Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol. 2, 4 (2004).","journal-title":"BMC Biol."},{"key":"227_CR60","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1021\/cr030110z","volume":"105","author":"TA Mukhtar","year":"2005","unstructured":"Mukhtar, T. A. & Wright, G. D. Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem. Rev. 105, 529\u2013542 (2005).","journal-title":"Chem. Rev."},{"key":"227_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijmm.2013.08.008","volume":"304","author":"Y Mast","year":"2014","unstructured":"Mast, Y. & Wohlleben, W. Streptogramins \u2013 Two are better than one. Int. J. Med. Microbiol. 304, 44\u201350 (2014).","journal-title":"Int. J. Med. Microbiol."},{"key":"227_CR62","doi-asserted-by":"crossref","unstructured":"Reissier, S. & Cattoir, V. Streptogramins for the treatment of infections caused by Gram-positive pathogens. Expert Rev. Anti-infective Ther., 1\u201313, (2020).","DOI":"10.1080\/14787210.2021.1834851"},{"key":"227_CR63","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2174\/1389450023347678","volume":"3","author":"NJ Johnston","year":"2002","unstructured":"Johnston, N. J., Mukhtar, T. A. & Wright, G. D. Streptogramin antibiotics: mode of action and resistance. Curr. Drug Targets 3, 335\u2013344 (2002).","journal-title":"Curr. Drug Targets"},{"key":"227_CR64","unstructured":"Inc, P. L. D. P. SYNERCID- quinupristin and dalfopristin injection, powder, lyophilized, for solution. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=712 (2018)."},{"key":"227_CR65","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00007611-200194030-00018","volume":"94","author":"M Summers","year":"2001","unstructured":"Summers, M., Misenhimer, G. R. & Antony, S. J. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin. South Med. J. 94, 353\u2013355 (2001).","journal-title":"South Med. J."},{"key":"227_CR66","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/46.5.775","volume":"46","author":"RH Drew","year":"2000","unstructured":"Drew, R. H. et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin\u2013dalfopristin in patients intolerant of or failing prior therapy. J. Antimicrobial Chemother. 46, 775\u2013784 (2000).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR67","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/jac\/dki108","volume":"55","author":"J Ng","year":"2005","unstructured":"Ng, J. & Gosbell, I. B. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J. Antimicrobial Chemother. 55, 1008\u20131012 (2005).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR68","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1128\/AAC.00212-10","volume":"54","author":"AB Reid","year":"2010","unstructured":"Reid, A. B., Daffy, J. R., Stanley, P. & Buising, K. L. Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital. Antimicrobial Agents Chemother. 54, 3949\u20133952 (2010).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR69","doi-asserted-by":"publisher","first-page":"106523","DOI":"10.1016\/j.ijantimicag.2022.106523","volume":"59","author":"AA Al-Fadhli","year":"2022","unstructured":"Al-Fadhli, A. A. et al. Macrolides from rare actinomycetes: structures and bioactivities. Int. J. Antimicrobial Agents 59, 106523 (2022).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1517\/13543784.11.2.189","volume":"11","author":"JM Blondeau","year":"2002","unstructured":"Blondeau, J. M., DeCarolis, E., Metzler, K. L. & Hansen, G. T. The macrolides. Expert Opin. Investigational Drugs 11, 189\u2013215 (2002).","journal-title":"Expert Opin. Investigational Drugs"},{"key":"227_CR71","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10295-013-1258-6","volume":"40","author":"D Kong","year":"2013","unstructured":"Kong, D., Lee, M.-J., Lin, S. & Kim, E.-S. Biosynthesis and pathway engineering of antifungal polyene macrolides in actinomycetes. J. Ind. Microbiol. Biotechnol. 40, 529\u2013543 (2013).","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"227_CR72","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/bph.13936","volume":"174","author":"GP Dinos","year":"2017","unstructured":"Dinos, G. P. The macrolide antibiotic renaissance. Br. J. Pharmacol. 174, 2967\u20132983 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"227_CR73","doi-asserted-by":"publisher","first-page":"111662","DOI":"10.1016\/j.ejmech.2019.111662","volume":"182","author":"A Janas","year":"2019","unstructured":"Janas, A. & Przybylski, P. 14- and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity. Eur. J. Medicinal Chem. 182, 111662 (2019).","journal-title":"Eur. J. Medicinal Chem."},{"key":"227_CR74","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","volume":"50","author":"M Barcia-Macay","year":"2006","unstructured":"Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M.-P., Tulkens, P. M. & Van Bambeke, F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrobial Agents Chemother. 50, 841\u2013851 (2006).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR75","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1128\/AAC.47.7.2283-2292.2003","volume":"47","author":"C Seral","year":"2003","unstructured":"Seral, C., Van Bambeke, F. & Tulkens, P. M. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrobial Agents Chemother. 47, 2283\u20132292 (2003).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR76","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003088-199834040-00003","volume":"34","author":"I Brook","year":"1998","unstructured":"Brook, I. Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance. Clin. Pharmacokinetics 34, 303\u2013310 (1998).","journal-title":"Clin. Pharmacokinetics"},{"key":"227_CR77","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/35101544","volume":"413","author":"F Schl\u00fcnzen","year":"2001","unstructured":"Schl\u00fcnzen, F. et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814\u2013821 (2001).","journal-title":"Nature"},{"key":"227_CR78","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ijantimicag.2007.11.014","volume":"31","author":"ES Cetin","year":"2008","unstructured":"Cetin, E. S., Gunes, H., Kaya, S., Aridogan, B. C. & Demirci, M. Macrolide-lincosamide-streptogramin B resistance phenotypes in clinical staphylococcal isolates. Int. J. Antimicrobal Agents 31, 364\u2013368 (2008).","journal-title":"Int. J. Antimicrobal Agents"},{"key":"227_CR79","first-page":"1335","volume":"85","author":"IA Osterman","year":"2020","unstructured":"Osterman, I. A., Dontsova, O. A. & Sergiev, P. V. rRNA methylation and antibiotic resistance. Biochemistry 85, 1335\u20131349 (2020).","journal-title":"Biochemistry"},{"key":"227_CR80","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3389\/fmicb.2018.01670","volume":"9","author":"F Iannelli","year":"2018","unstructured":"Iannelli, F. et al. Type m resistance to macrolides is due to a two-gene efflux transport system of the ATP-binding cassette (ABC) superfamily. Front. Microbiol. 9, 1670 (2018).","journal-title":"Front. Microbiol"},{"key":"227_CR81","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1128\/AAC.40.8.1817","volume":"40","author":"J Sutcliffe","year":"1996","unstructured":"Sutcliffe, J., Tait-Kamradt, A. & Wondrack, L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrobial Agents Chemother. 40, 1817\u20131824 (1996).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR82","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1128\/AAC.43.12.2823","volume":"43","author":"MC Roberts","year":"1999","unstructured":"Roberts, M. C. et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrobial Agents Chemother. 43, 2823\u20132830 (1999).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijantimicag.2003.11.003","volume":"23","author":"B Bozdogan","year":"2004","unstructured":"Bozdogan, B. & Appelbaum, P. C. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrobial Agents 23, 113\u2013119 (2004).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR84","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1128\/AAC.41.10.2127","volume":"41","author":"AH Lin","year":"1997","unstructured":"Lin, A. H., Murray, R. W., Vidmar, T. J. & Marotti, K. R. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrobial Agents Chemother. 41, 2127\u20132131 (1997).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR85","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","volume":"358","author":"DJ Diekema","year":"2001","unstructured":"Diekema, D. J. & Jones, R. N. Oxazolidinone antibiotics. Lancet 358, 1975\u20131982 (2001).","journal-title":"Lancet"},{"key":"227_CR86","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1101\/gr.089342.108","volume":"19","author":"J Feng","year":"2009","unstructured":"Feng, J. et al. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 19, 1214\u20131223 (2009).","journal-title":"Genome Res."},{"key":"227_CR87","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1086\/313597","volume":"30","author":"JW Chien","year":"2000","unstructured":"Chien, J. W., Kucia, M. L. & Salata, R. A. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30, 146\u2013151 (2000).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR88","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.clinthera.2006.08.001","volume":"28","author":"E Senneville","year":"2006","unstructured":"Senneville, E. et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: A retrospective study. Clin. Therapeutics 28, 1155\u20131163 (2006).","journal-title":"Clin. Therapeutics"},{"key":"227_CR89","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1179\/joc.2005.17.6.643","volume":"17","author":"CO Aneziokoro","year":"2005","unstructured":"Aneziokoro, C. O., Cannon, J. P., Pachucki, C. T. & Lentino, J. R. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J. Chemother. 17, 643\u2013650 (2005).","journal-title":"J. Chemother."},{"key":"227_CR90","doi-asserted-by":"crossref","unstructured":"Vercillo, M., Patzakis, M. J., Holtom, P. & Zalavras, C. G. Linezolid in the treatment of implant-related chronic osteomyelitis. Clin. Orthopaedics Related Research\u00ae 461 (2007).","DOI":"10.1097\/BLO.0b013e3180986d60"},{"key":"227_CR91","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1128\/AAC.44.12.3438-3440.2000","volume":"44","author":"R Patel","year":"2000","unstructured":"Patel, R., Piper, K. E., Rouse, M. S. & Steckelberg, J. M. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrobial Agents Chemother. 44, 3438\u20133440 (2000).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s15010-004-3029-9","volume":"32","author":"CR Rayner","year":"2004","unstructured":"Rayner, C. R. et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 32, 8\u201314 (2004).","journal-title":"Infection"},{"key":"227_CR93","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1086\/313897","volume":"31","author":"M Melzer","year":"2000","unstructured":"Melzer, M., Goldsmith, D. & Gransden, W. Successful Ttreatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus Bacteremias. Clin. Infect. Dis. 31, 208\u2013209 (2000).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/dkf066","volume":"50","author":"A Lovering","year":"2002","unstructured":"Lovering, A. et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrobial Chemother. 50, 73\u201377 (2002).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR95","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1128\/AAC.01724-09","volume":"54","author":"S Lemaire","year":"2010","unstructured":"Lemaire, S. et al. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrobial Agents Chemother. 54, 2549\u20132559 (2010).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR96","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1128\/AAC.01723-09","volume":"54","author":"S Lemaire","year":"2010","unstructured":"Lemaire, S., Tulkens Paul, M. & Van Bambeke, F. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: Studies with macrophages and polymorphonuclear neutrophils. Antimicrobial Agents Chemother. 54, 2540\u20132548 (2010).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR97","doi-asserted-by":"publisher","first-page":"8095","DOI":"10.2147\/IJN.S179380","volume":"13","author":"X Yang","year":"2018","unstructured":"Yang, X., Shi, G., Guo, J., Wang, C. & He, Y. Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus. Int. J. Nanomed. 13, 8095 (2018).","journal-title":"Int. J. Nanomed."},{"key":"227_CR98","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jac\/dky473","volume":"74","author":"L Abad","year":"2019","unstructured":"Abad, L. et al. Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting. J. Antimicrobial Chemother. 74, 625\u2013632 (2019).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR99","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejpb.2020.04.010","volume":"151","author":"P Guo","year":"2020","unstructured":"Guo, P., Buttaro, B. A., Xue, H. Y., Tran, N. T. & Wong, H. L. Lipid-polymer hybrid nanoparticles carrying linezolid improve treatment of methicillin-resistant Staphylococcus aureus (MRSA) harbored inside bone cells and biofilms. Eur. J. Pharmaceutics Biopharmaceutics 151, 189\u2013198 (2020).","journal-title":"Eur. J. Pharmaceutics Biopharmaceutics"},{"key":"227_CR100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06354.x","volume":"1241","author":"ML Nelson","year":"2011","unstructured":"Nelson, M. L. & Levy, S. B. The history of the tetracyclines. Ann. N. Y. Acad. Sci. 1241, 17\u201332 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"227_CR101","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1086\/367622","volume":"36","author":"GM Eliopoulos","year":"2003","unstructured":"Eliopoulos, G. M., Eliopoulos, G. M. & Roberts, M. C. Tetracycline therapy: Update. Clin. Infect. Dis. 36, 462\u2013467 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR102","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1128\/AAC.47.12.3675-3681.2003","volume":"12","author":"SR Connell","year":"2003","unstructured":"Connell, S. R., Tracz, D. M., Nierhaus, K. H. & Taylor, D. E. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrobial Agents Chemother. 12, 3675\u20133681 (2003).","journal-title":"Antimicrobial Agents Chemother"},{"key":"227_CR103","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra, I. & Roberts, M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232\u2013260 (2001).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"227_CR104","doi-asserted-by":"publisher","DOI":"10.1007\/s40828-021-00138-x","volume":"7","author":"R Ramachanderan","year":"2021","unstructured":"Ramachanderan, R. & Schaefer, B. Tetracycline antibiotics. ChemTexts 7, 18 (2021).","journal-title":"ChemTexts"},{"key":"227_CR105","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.1016\/S0924-8579(09)70005-6","volume":"32","author":"LR Peterson","year":"2008","unstructured":"Peterson, L. R. A review of tigecycline \u2014 the first glycylcycline. Int. J. Antimicrobial Agents 32, S215\u2013S222 (2008).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR106","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2013.07.014","volume":"77","author":"AT Griffin","year":"2013","unstructured":"Griffin, A. T., Harting, J. A. & Christensen, D. M. Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Diagnostic Microbiol. Infect. Dis. 77, 273\u2013277 (2013).","journal-title":"Diagnostic Microbiol. Infect. Dis."},{"key":"227_CR107","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/cir842","volume":"54","author":"B Spellberg","year":"2012","unstructured":"Spellberg, B. & Lipsky, B. A. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin. Infect. Dis. 54, 393\u2013407 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-13-267","volume":"13","author":"CA Kreis","year":"2013","unstructured":"Kreis, C. A. et al. Therapy of intracellular Staphylococcus aureus by tigecyclin. BMC Infect. Dis. 13, 1\u20136 (2013).","journal-title":"BMC Infect. Dis."},{"key":"227_CR109","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1016\/S0040-4020(01)93759-7","volume":"35","author":"WO Godtfredsen","year":"1979","unstructured":"Godtfredsen, W. O., Rastrup-Andersen, N., Vangedal, S. & Ollis, W. D. Metabolites of fusidium coccineum. Tetrahedron 35, 2419\u20132431 (1979).","journal-title":"Tetrahedron"},{"key":"227_CR110","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/10408347.2015.1084225","volume":"46","author":"MM Curbete","year":"2016","unstructured":"Curbete, M. M. & Salgado, H. R. N. A critical review of the properties of fusidic acid and analytical methods for its determination. Crit. Rev. Anal. Chem. 46, 352\u2013360 (2016).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"227_CR111","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1006\/jmbi.2000.4168","volume":"303","author":"M Laurberg","year":"2000","unstructured":"Laurberg, M. et al. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site11Edited by I. A. Wilson. J. Mol. Biol. 303, 593\u2013603 (2000).","journal-title":"J. Mol. Biol."},{"key":"227_CR112","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/cid\/ciw665","volume":"63","author":"R Pushkin","year":"2016","unstructured":"Pushkin, R. et al. A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: A newly identified drug\u2013drug interaction. Clin. Infect. Dis. 63, 1599\u20131604 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR113","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/147323000203000509","volume":"30","author":"M Ertek","year":"2002","unstructured":"Ertek, M., Yazgi, H., Erol, S. & Altoparlak, U. Demonstration of in vitro antagonism between fusidic acid and quinolones. J. Int. Med. Res. 30, 525\u2013528 (2002).","journal-title":"J. Int. Med. Res."},{"key":"227_CR114","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13756-021-00943-6","volume":"10","author":"B Hajikhani","year":"2021","unstructured":"Hajikhani, B. et al. The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis. Antimicrobial Resistance Infect. Control 10, 75 (2021).","journal-title":"Antimicrobial Resistance Infect. Control"},{"key":"227_CR115","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1128\/AAC.01542-06","volume":"51","author":"AJ O\u2019Neill","year":"2007","unstructured":"O\u2019Neill, A. J., McLaws, F., Kahlmeter, G., Henriksen, A. S. & Chopra, I. Genetic basis of resistance to fusidic acid in staphylococci. Antimicrobial Agents Chemother. 51, 1737\u20131740 (2007).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR116","first-page":"92","volume":"32","author":"M Inam","year":"2020","unstructured":"Inam, M. & Shabir, M. Frequency of different bacteria and their antibiotics sensitivity pattern in chronic osteomyelitis. J. Pak. Orthop. Assoc. 32, 92\u201396 (2020).","journal-title":"J. Pak. Orthop. Assoc."},{"key":"227_CR117","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijantimicag.2012.03.010","volume":"40","author":"J-L Wang","year":"2012","unstructured":"Wang, J.-L. et al. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Int. J. Antimicrobial Agents 40, 103\u2013107 (2012).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR118","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1469-0691.2007.01691.x","volume":"13","author":"CA Aboltins","year":"2007","unstructured":"Aboltins, C. A. et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin. Microbiol. Infect. 13, 586\u2013591 (2007).","journal-title":"Clin. Microbiol. Infect."},{"key":"227_CR119","first-page":"597","volume":"39","author":"EJ Begg","year":"1995","unstructured":"Begg, E. J. & Barclay, M. L. Aminoglycosides-50 years on. Br. J. Clin. Pharmacol. 39, 597 (1995).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"227_CR120","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2165\/11597020-000000000-00000","volume":"71","author":"S Pagkalis","year":"2011","unstructured":"Pagkalis, S., Mantadakis, E., Mavros, M. N., Ammari, C. & Falagas, M. E. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs 71, 2277\u20132294 (2011).","journal-title":"Drugs"},{"key":"227_CR121","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11373-007-9194-y","volume":"15","author":"S Shakil","year":"2008","unstructured":"Shakil, S., Khan, R., Zarrilli, R. & Khan, A. U. Aminoglycosides versus bacteria \u2013 a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci. 15, 5\u201314 (2008).","journal-title":"J. Biomed. Sci."},{"key":"227_CR122","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.idc.2020.06.002","volume":"34","author":"J-I Wachino","year":"2020","unstructured":"Wachino, J.-I., Doi, Y. & Arakawa, Y. Aminoglycoside resistance: updates with a focus on acquired 16S ribosomal RNA methyltransferases. Infect. Dis. Clin. 34, 887\u2013902 (2020).","journal-title":"Infect. Dis. Clin."},{"key":"227_CR123","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijantimicag.2011.03.008","volume":"38","author":"RE Barth","year":"2011","unstructured":"Barth, R. E., Vogely, H. C., Hoepelman, A. I. M. & Peters, E. J. G. \u2018To bead or not to bead?\u2019 Treatment of osteomyelitis and prosthetic joint-associated infections with gentamicin bead chains. Int. J. Antimicrobial Agents 38, 371\u2013375 (2011).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR124","doi-asserted-by":"publisher","first-page":"e00119","DOI":"10.1128\/IAI.00119-19","volume":"87","author":"J-H Kim","year":"2019","unstructured":"Kim, J.-H., Chaurasia, A. K., Batool, N., Ko, K. S. & Kim, K. K. Alternative enzyme protection assay to overcome the drawbacks of the gentamicin protection assay for measuring entry and intracellular survival of staphylococci. Infect. Immunity 87, e00119\u201319 (2019).","journal-title":"Infect. Immunity"},{"key":"227_CR125","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1128\/AAC.00285-12","volume":"56","author":"L Garcia","year":"2012","unstructured":"Garcia, L. et al. Pharmacodynamic evaluation of the activity of antibiotics against hemin-and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Antimicrobial Agents Chemother. 56, 3700\u20133711 (2012).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR126","doi-asserted-by":"publisher","first-page":"258","DOI":"10.22203\/eCM.v028a18","volume":"28","author":"W Mohamed","year":"2014","unstructured":"Mohamed, W. et al. Intracellular proliferation of S. aureus in osteoblasts and effects of rifampicin and gentamicin on S. aureus intracellular proliferation and survival. Eur. Cells Mater. 28, 258\u2013268 (2014).","journal-title":"Eur. Cells Mater."},{"key":"227_CR127","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1078\/1438-4221-00282","volume":"293","author":"F Schaaff","year":"2003","unstructured":"Schaaff, F., Bierbaum, G., Baumert, N., Bartmann, P. & Sahl, H.-G. Mutations are involved in emergence of aminoglycoside-induced small colony variants of Staphylococcus aureus. Int. J. Med. Microbiol. 293, 427\u2013435 (2003).","journal-title":"Int. J. Med. Microbiol."},{"key":"227_CR128","first-page":"324","volume":"94","author":"LL Pelletier","year":"1979","unstructured":"Pelletier, L. L., Richardson, M. & Feist, M. Virulent gentamicin-induced small colony variants of Staphylococcus aureus. J. Lab. Clin. Med. 94, 324\u2013334 (1979).","journal-title":"J. Lab. Clin. Med."},{"key":"227_CR129","doi-asserted-by":"publisher","first-page":"14299","DOI":"10.1021\/acsami.7b15678","volume":"10","author":"S Yang","year":"2018","unstructured":"Yang, S. et al. Bacteria-targeting nanoparticles with microenvironment-responsive antibiotic release to eliminate intracellular Staphylococcus aureus and associated infection. ACS Appl. Mater. Interfaces 10, 14299\u201314311 (2018).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"227_CR130","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.survophthal.2004.01.005","volume":"49","author":"JM Blondeau","year":"2004","unstructured":"Blondeau, J. M. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv. Ophthalmol. 49, S73\u2013S78 (2004).","journal-title":"Surv. Ophthalmol."},{"key":"227_CR131","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/11587280-000000000-00000","volume":"34","author":"AM Tom\u00e9","year":"2011","unstructured":"Tom\u00e9, A. M. & Filipe, A. Quinolones. Drug Saf. 34, 465\u2013488 (2011).","journal-title":"Drug Saf."},{"key":"227_CR132","unstructured":"Yan, A. & Bryant, E. E. Quinolones. StatPearls, Internet Book at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557777\/ (2020)."},{"key":"227_CR133","first-page":"301","volume":"71","author":"TV Dukhovich","year":"2018","unstructured":"Dukhovich, T. V., Chopei, I. V. & Chubirko, K. I. Dynamics of staphylococcus aureus antibiotic resistance to fluoroquinolones in vitro in patients with overweight. Wiad. Lek. 71, 301\u2013305 (2018).","journal-title":"Wiad. Lek."},{"key":"227_CR134","first-page":"258","volume":"23","author":"M Fantoni","year":"2019","unstructured":"Fantoni, M., Taccari, F. & Giovannenze, F. Systemic antibiotic treatment of chronic osteomyelitis in adults. Eur. Rev. Med. Pharm. Sci. 23, 258\u2013270 (2019).","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"227_CR135","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ijantimicag.2019.06.018","volume":"54","author":"M\u00c1 Mel\u00e9ndez-Carmona","year":"2019","unstructured":"Mel\u00e9ndez-Carmona, M. \u00c1., Mu\u00f1oz-Gallego, I., Viedma, E., Lora-Tamayo, J. & Chaves, F. Intraosteoblastic activity of levofloxacin and rifampin alone and in combination against clinical isolates of meticillin-susceptible Staphylococcus aureus causing prosthetic joint infection. Int. J. Antimicrobial Agents 54, 356\u2013360 (2019).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR136","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1089\/ten.tea.2014.0605","volume":"21","author":"AG Krishnan","year":"2015","unstructured":"Krishnan, A. G., Jayaram, L., Biswas, R. & Nair, M. Evaluation of antibacterial activity and cytocompatibility of ciprofloxacin loaded Gelatin\u2013Hydroxyapatite scaffolds as a local drug delivery system for osteomyelitis treatment. Tissue Eng. Part A 21, 1422\u20131431 (2015).","journal-title":"Tissue Eng. Part A"},{"key":"227_CR137","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ijpharm.2017.08.089","volume":"532","author":"M Ferreira","year":"2017","unstructured":"Ferreira, M. et al. Levofloxacin-loaded bone cement delivery system: Highly effective against intracellular bacteria and Staphylococcus aureus biofilms. Int. J. Pharmaceutics 532, 241\u2013248 (2017).","journal-title":"Int. J. Pharmaceutics"},{"key":"227_CR138","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1099\/ijs.0.02901-0","volume":"54","author":"S Bala","year":"2004","unstructured":"Bala, S. et al. Reclassification of Amycolatopsis mediterranei DSM 46095 as Amycolatopsis rifamycinica sp. nov. Int. J. Syst. Evolut. Microbiol. 54, 1145\u20131149 (2004).","journal-title":"Int. J. Syst. Evolut. Microbiol."},{"key":"227_CR139","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","volume":"51","author":"MI Hutchings","year":"2019","unstructured":"Hutchings, M. I., Truman, A. W. & Wilkinson, B. Antibiotics: past, present and future. Curr. Opin. Microbiol. 51, 72\u201380 (2019).","journal-title":"Curr. Opin. Microbiol."},{"key":"227_CR140","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","volume":"90","author":"PA Aristoff","year":"2010","unstructured":"Aristoff, P. A., Garcia, G. A., Kirchhoff, P. D. & Hollis Showalter, H. D. Rifamycins \u2013 obstacles and opportunities. Tuberculosis 90, 94\u2013118 (2010).","journal-title":"Tuberculosis"},{"key":"227_CR141","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1302\/2046-3758.92.BJR-2019-0131.R1","volume":"9","author":"K Yu","year":"2020","unstructured":"Yu, K. et al. Recalcitrant methicillin-resistant Staphylococcus aureus infection of bone cells: Intracellular penetration and control strategies. Bone Jt. Res. 9, 49\u201359 (2020).","journal-title":"Bone Jt. Res."},{"key":"227_CR142","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jac\/dkaa061","volume":"75","author":"L Abad","year":"2020","unstructured":"Abad, L. et al. Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin. J. Antimicrobial Chemother. 75, 1466\u20131473 (2020).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR143","doi-asserted-by":"publisher","first-page":"119784","DOI":"10.1016\/j.ijpharm.2020.119784","volume":"589","author":"P Guo","year":"2020","unstructured":"Guo, P., Xue, H. Y., Buttaro, B. A., Tran, N. T. & Wong, H. L. Enhanced eradication of intracellular and biofilm-residing methicillin-resistant Staphylococcus aureus (MRSA) reservoirs with hybrid nanoparticles delivering rifampicin. Int. J. Pharmaceutics 589, 119784 (2020).","journal-title":"Int. J. Pharmaceutics"},{"key":"227_CR144","doi-asserted-by":"publisher","first-page":"e02231","DOI":"10.1128\/AAC.02231-19","volume":"64","author":"C Kolenda","year":"2020","unstructured":"Kolenda, C. et al. Evaluation of the activity of a combination of three bacteriophages alone or in association with antibiotics on Staphylococcus aureus embedded in biofilm or internalized in osteoblasts. Antimicrobial Agents Chemother. 64, e02231\u201319 (2020).","journal-title":"Antimicrobial Agents Chemother"},{"key":"227_CR145","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1007\/s11999-015-4300-3","volume":"473","author":"CJ Sanchez","year":"2015","unstructured":"Sanchez, C. J. et al. Rifamycin derivatives are effective against staphylococcal biofilms in vitro and elutable from PMMA. Clin. Orthop. Relat. Res. 473, 2874\u20132884 (2015).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"227_CR146","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/infdis\/jiaa401","volume":"222","author":"MJ Karau","year":"2020","unstructured":"Karau, M. J. et al. Novel use of rifabutin and rifapentine to treat methicillin-resistant Staphylococcus aureus in a rat model of foreign body osteomyelitis. J. Infect. Dis. 222, 1498\u20131504 (2020).","journal-title":"J. Infect. Dis."},{"key":"227_CR147","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","volume":"6","author":"K Bush","year":"2016","unstructured":"Bush, K. & Bradford, P. A. \u03b2-Lactams and \u03b2-lactamase inhibitors: an overview. Cold Spring Harb. Perspect. Med. 6, a025247 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"227_CR148","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/0002-9343(92)90600-G","volume":"92","author":"RD Cooper","year":"1992","unstructured":"Cooper, R. D. The carbacephems: a new beta-lactam antibiotic class. Am. J. Med. 92, S2\u2013S6 (1992).","journal-title":"Am. J. Med."},{"key":"227_CR149","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jac\/37.1.53","volume":"37","author":"G Bignardi","year":"1996","unstructured":"Bignardi, G., Woodford, N., Chapman, A., Johnson, A. & Speller, D. Detection of the mec-A gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillin resistance. J. Antimicrobial Chemother. 37, 53\u201363 (1996).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR150","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/jac\/dki094","volume":"55","author":"S Lemaire","year":"2005","unstructured":"Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M.-P. & Tulkens, P. M. Activity of three \u03b2-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrobial Chemother. 55, 897\u2013904 (2005).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR151","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10006-018-0732-8","volume":"22","author":"M Akashi","year":"2018","unstructured":"Akashi, M. et al. A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw. Oral. Maxillofac. Surg. 22, 369\u2013378 (2018).","journal-title":"Oral. Maxillofac. Surg."},{"key":"227_CR152","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/jor.23723","volume":"36","author":"DH Dusane","year":"2018","unstructured":"Dusane, D. H. et al. Targeting intracellular Staphylococcus aureus to lower recurrence of orthopaedic infection. J. Orthop. Res. 36, 1068\u20131092 (2018).","journal-title":"J. Orthop. Res."},{"key":"227_CR153","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1093\/jac\/dkx314","volume":"72","author":"C Dupieux","year":"2017","unstructured":"Dupieux, C. et al. Intraosteoblastic activity of daptomycin in combination with oxacillin and ceftaroline against MSSA and MRSA. J. Antimicrobial Chemother. 72, 3353\u20133356 (2017).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR154","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1128\/AAC.31.3.410","volume":"31","author":"C Renard","year":"1987","unstructured":"Renard, C., Vanderhaeghe, H. J., Claes, P. J., Zenebergh, A. & Tulkens, P. M. Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages. Antimicrobial Agents Chemother. 31, 410\u2013416 (1987).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR155","doi-asserted-by":"publisher","first-page":"12769","DOI":"10.1074\/jbc.M800079200","volume":"283","author":"S Lemaire","year":"2008","unstructured":"Lemaire, S., Fuda, C., Van Bambeke, F., Tulkens, P. M. & Mobashery, S. Restoration of susceptibility of methicillin-resistant Staphylococcus aureus to \u03b2-lactam antibiotics by acidic pH: role of penicillin-binding protein PBP 2a. J. Biol. Chem. 283, 12769\u201312776 (2008).","journal-title":"J. Biol. Chem."},{"key":"227_CR156","doi-asserted-by":"publisher","first-page":"034114","DOI":"10.1088\/1748-6041\/3\/3\/034114","volume":"3","author":"RR Pillai","year":"2008","unstructured":"Pillai, R. R., Somayaji, S. N., Rabinovich, M., Hudson, M. C. & Gonsalves, K. E. Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis. Biomed. Mater. 3, 034114 (2008).","journal-title":"Biomed. Mater."},{"key":"227_CR157","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1021\/acsabm.8b00821","volume":"2","author":"C Zhang","year":"2019","unstructured":"Zhang, C. et al. Antibiotic-derived lipid nanoparticles to treat intracellular Staphylococcus aureus. ACS Appl. Bio Mater. 2, 1270\u20131277 (2019).","journal-title":"ACS Appl. Bio Mater."},{"key":"227_CR158","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/ajhp\/zxaa076","volume":"77","author":"MH Scheetz","year":"2020","unstructured":"Scheetz, M. H. Vancomycin: The pendulum swings. Am. J. Health-Syst. Pharm. 77, 810\u2013811 (2020).","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"227_CR159","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/acsinfecdis.7b00258","volume":"4","author":"MA Blaskovich","year":"2018","unstructured":"Blaskovich, M. A. et al. Developments in glycopeptide antibiotics. ACS Infect. Dis. 4, 715\u2013735 (2018).","journal-title":"ACS Infect. Dis."},{"key":"227_CR160","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pro.3819","volume":"29","author":"PJ Stogios","year":"2020","unstructured":"Stogios, P. J. & Savchenko, A. Molecular mechanisms of vancomycin resistance. Protein Sci. 29, 654\u2013669 (2020).","journal-title":"Protein Sci."},{"key":"227_CR161","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1086\/491711","volume":"42","author":"P Courvalin","year":"2006","unstructured":"Courvalin, P. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42, S25\u2013S34 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR162","doi-asserted-by":"publisher","first-page":"112497","DOI":"10.1016\/j.ejmech.2020.112497","volume":"202","author":"IG Shahin","year":"2020","unstructured":"Shahin, I. G. et al. Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections. Eur. J. Medicinal Chem. 202, 112497 (2020).","journal-title":"Eur. J. Medicinal Chem."},{"key":"227_CR163","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijantimicag.2010.10.011","volume":"37","author":"A Pumerantz","year":"2011","unstructured":"Pumerantz, A. et al. Preparation of liposomal vancomycin and intracellular killing of meticillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrobial Agents 37, 140\u2013144 (2011).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR164","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1021\/acsinfecdis.0c00264","volume":"6","author":"S Huo","year":"2020","unstructured":"Huo, S. et al. Overcoming planktonic and intracellular Staphylococcus aureus-associated infection with a cell-penetrating peptide-conjugated antimicrobial peptide. ACS Infect. Dis. 6, 3147\u20133162 (2020).","journal-title":"ACS Infect. Dis."},{"key":"227_CR165","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2147\/IJN.S127715","volume":"12","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Efficient induction of antimicrobial activity with vancomycin nanoparticle-loaded poly (trimethylene carbonate) localized drug delivery system. Int. J. Nanomed. 12, 1201 (2017).","journal-title":"Int. J. Nanomed."},{"key":"227_CR166","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jconrel.2020.11.045","volume":"329","author":"X Yang","year":"2021","unstructured":"Yang, X. et al. Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes. J. Controlled Release 329, 454\u2013467 (2021).","journal-title":"J. Controlled Release"},{"key":"227_CR167","doi-asserted-by":"publisher","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","volume":"7","author":"LL Silver","year":"2017","unstructured":"Silver, L. L. Fosfomycin: Mechanism and resistance. Cold Spring Harb. Perspect. Med. 7, a025262 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"227_CR168","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","volume":"53","author":"ME Falagas","year":"2019","unstructured":"Falagas, M. E., Athanasaki, F., Voulgaris, G. L., Triarides, N. A. & Vardakas, K. Z. Resistance to fosfomycin: Mechanisms, frequency and clinical consequences. Int. J. Antimicrobial Agents 53, 22\u201328 (2019).","journal-title":"Int. J. Antimicrobial Agents"},{"key":"227_CR169","first-page":"30","volume":"32","author":"L Morata","year":"2019","unstructured":"Morata, L. & Soriano, A. The role of fosfomycin in osteoarticular infection. Rev. Espa\u00f1ola de. Quimioterapia 32, 30 (2019).","journal-title":"Rev. Espa\u00f1ola de. Quimioterapia"},{"key":"227_CR170","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","volume":"23","author":"B Grabein","year":"2017","unstructured":"Grabein, B., Graninger, W., Rodr\u00edguez Ba\u00f1o, J., Dinh, A. & Liesenfeld, D. B. Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature. Clin. Microbiol. Infect. 23, 363\u2013372 (2017).","journal-title":"Clin. Microbiol. Infect."},{"key":"227_CR171","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-0716-1358-0_20","volume":"2296","author":"S Rubio","year":"2021","unstructured":"Rubio, S., Mart\u00ednez-C\u00e1mara, S., de la Fuente, J. L., Rodr\u00edguez-S\u00e1iz, M. & Barredo, J.-L. Strain improvement program of Streptomyces roseosporus for daptomycin production. Methods Mol. Biol. 2296, 351\u2013363 (2021).","journal-title":"Methods Mol. Biol."},{"key":"227_CR172","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2174\/1389557511209030202","volume":"12","author":"C Vilhena","year":"2012","unstructured":"Vilhena, C. & Bettencourt, A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev. Medicinal Chem. 12, 202\u2013209 (2012).","journal-title":"Mini Rev. Medicinal Chem."},{"key":"227_CR173","doi-asserted-by":"publisher","first-page":"183395","DOI":"10.1016\/j.bbamem.2020.183395","volume":"1862","author":"HWDaptomycin Huang","year":"2020","unstructured":"Huang, H. W. Daptomycin its membrane-active mechanism vs. that of other antimicrobial peptides. Biochimica et. Biophysica Acta (BBA) - Biomembranes 1862, 183395 (2020).","journal-title":"Biochimica et. Biophysica Acta (BBA) - Biomembranes"},{"key":"227_CR174","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.12948","volume":"1354","author":"TT Tran","year":"2015","unstructured":"Tran, T. T., Munita, J. M. & Arias, C. A. Mechanisms of drug resistance: daptomycin resistance. Ann. N. Y. Acad. Sci. 1354, 32 (2015).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"227_CR175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkx349","volume":"73","author":"M Heidary","year":"2018","unstructured":"Heidary, M. et al. Daptomycin. J. Antimicrobial Chemother. 73, 1\u201311 (2018).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR176","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bjid.2019.05.006","volume":"23","author":"JP Telles","year":"2019","unstructured":"Telles, J. P., Cieslinski, J. & Tuon, F. F. Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review. Braz. J. Infect. Dis. 23, 191\u2013196 (2019).","journal-title":"Braz. J. Infect. Dis."},{"key":"227_CR177","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.idnow.2021.01.009","volume":"51","author":"O Sipahi","year":"2021","unstructured":"Sipahi, O. et al. Daptomycin versus teicoplanin in the treatment of osteomyelitis: Results of the G\u00f6ztepe retrospective cohort study. Infectious Diseases Now 51, 362\u2013367 (2021).","journal-title":"Infectious Diseases Now"},{"key":"227_CR178","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ijpharm.2018.08.048","volume":"550","author":"A-K Woischnig","year":"2018","unstructured":"Woischnig, A.-K. et al. Acrylic microparticles increase daptomycin intracellular and in vivo anti-biofilm activity against Staphylococcus aureus. Int. J. pharmaceutics 550, 372\u2013379 (2018).","journal-title":"Int. J. pharmaceutics"},{"key":"227_CR179","doi-asserted-by":"publisher","first-page":"e01275","DOI":"10.1128\/AAC.01275-20","volume":"65","author":"C Fisher","year":"2021","unstructured":"Fisher, C. & Patel, R. Rifampin, rifapentine, and rifabutin are active against intracellular periprosthetic joint infection associated Staphylococcus epidermidis. Antimicrobial Agents Chemother. 65, e01275\u201320 (2021).","journal-title":"Antimicrobial Agents Chemother"},{"key":"227_CR180","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0022-5347(17)53227-9","volume":"128","author":"JJ Schentag","year":"1982","unstructured":"Schentag, J. J., Gengo, F. M. & Tsuang, M. T. Principles of antibiotic tissue penetration and guidelines for pharmacokinetic analysis. J. Urol. 128, 871\u2013872 (1982).","journal-title":"J. Urol."},{"key":"227_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-014-0207-5","volume":"14","author":"T Hamza","year":"2014","unstructured":"Hamza, T. & Li, B. Differential responses of osteoblasts and macrophages upon Staphylococcus aureus infection. BMC Microbiol. 14, 207 (2014).","journal-title":"BMC Microbiol."},{"key":"227_CR182","doi-asserted-by":"publisher","first-page":"781022","DOI":"10.3389\/fcimb.2021.781022","volume":"11","author":"NJ Gunn","year":"2021","unstructured":"Gunn, N. J. et al. A human osteocyte cell line model for studying Staphylococcus aureus persistence in osteomyelitis. Front. Cellular Infect. Microbiol. 11, 781022 (2021).","journal-title":"Front. Cellular Infect. Microbiol"},{"key":"227_CR183","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3389\/fmicb.2020.01415","volume":"11","author":"N H\u00e4ffner","year":"2020","unstructured":"H\u00e4ffner, N. et al. Intracellular environment and agr system affect colony size heterogeneity of Staphylococcus aureus. Frontiers in Microbiology 11, 1415 (2020).","journal-title":"Frontiers in Microbiology"},{"key":"227_CR184","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1302\/2046-3758.113.BJR-2021-0268.R1","volume":"11","author":"J Goetz","year":"2022","unstructured":"Goetz, J. et al. Animal experimental investigation on the efficacy of antibiotic therapy with linezolid, vancomycin, cotrimoxazole, and rifampin in treatment of periprosthetic knee joint infections by MRSA. Bone Jt. Res. 11, 143\u2013151 (2022).","journal-title":"Bone Jt. Res."},{"key":"227_CR185","doi-asserted-by":"crossref","first-page":"2050313X1984146","DOI":"10.1177\/2050313X19841465","volume":"7","author":"K Sato","year":"2019","unstructured":"Sato, K. et al. Osteomyelitis due to methicillin-resistant Staphylococcus aureus successfully treated by an oral combination of minocycline and trimethoprim\u2013sulfamethoxazole. SAGE Open Med. Case Rep. 7, 2050313X19841465 (2019).","journal-title":"SAGE Open Med. Case Rep."},{"key":"227_CR186","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/jac\/dkab341","volume":"77","author":"D Nurjadi","year":"2022","unstructured":"Nurjadi, D. et al. Molecular analysis of an increase in trimethoprim\/sulfamethoxazole-resistant MRSA reveals multiple introductions into a tertiary care hospital, Germany 2012\u201319. J. Antimicrobial Chemother. 77, 38\u201348 (2022).","journal-title":"J. Antimicrobial Chemother."},{"key":"227_CR187","doi-asserted-by":"publisher","unstructured":"Ham, D. C. et al. Trimethoprim-sulfamethoxazole resistance patterns among Staphylococcus aureus in the United States, 2012\u20132018. Infect. Control Hospital Epidemiology https:\/\/doi.org\/10.1017\/ice.2022.9 (2022).","DOI":"10.1017\/ice.2022.9"},{"key":"227_CR188","doi-asserted-by":"publisher","first-page":"e01703","DOI":"10.1128\/AAC.01703-21","volume":"66","author":"MJ Karau","year":"2022","unstructured":"Karau, M. J. et al. Activity of omadacycline in rat methicillin-resistant staphylococcus aureus osteomyelitis. Antimicrobial Agents Chemother. 66, e01703\u2013e01721 (2022).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR189","doi-asserted-by":"publisher","first-page":"e01972","DOI":"10.1128\/AAC.01972-19","volume":"64","author":"J Dubois","year":"2020","unstructured":"Dubois, J., Dubois, M. & Martel, J.-F. In vitro and intracellular activities of omadacycline against Legionella pneumophila. Antimicrobial Agents Chemother. 64, e01972\u201301919 (2020).","journal-title":"Antimicrobial Agents Chemother."},{"key":"227_CR190","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky, J. A., Steenbergen, J. & Zhanel, G. G. Microbiology and preclinical review of omadacycline. Clin. Infect. Dis. 69, S6\u2013S15 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"227_CR191","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.bjid.2013.12.005","volume":"18","author":"ALL Lima","year":"2014","unstructured":"Lima, A. L. L., Oliveira, P. R., Carvalho, V. C., Cimerman, S. & Savio, E. Recommendations for the treatment of osteomyelitis. Braz. J. Infect. Dis. 18, 526\u2013534 (2014).","journal-title":"Braz. J. Infect. Dis."}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41413-022-00227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-022-00227-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-022-00227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T10:05:36Z","timestamp":1700906736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41413-022-00227-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":191,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["227"],"URL":"https:\/\/doi.org\/10.1038\/s41413-022-00227-8","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}